ReviewEuropean journal of immunology2021
CAR T cells: Building on the CD19 paradigm.
Review in European journal of immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Review: progression and heterogeneity of multiple sources of mesenchymal stromal cells for the treatment of rheumatoid arthritis.Stem cell research & therapy · 2025Pooled it
- Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.Transplantation and cellular therapy · 2022Guideline
- Progress in the development of cytokine armoured CAR T cells.Nature reviews. Immunology · 2026Review
- Invariant Natural Killer T Cells in Cancer Immunotherapy: Lipid-Based Modulation, Nanotechnology, and Translational Advances.International journal of molecular sciences · 2026Review
- Rapid assessment of immune effector cell-mediated cytotoxicity using mRNA lipid nanoparticles.Frontiers in immunology · 2026Article
- Anti-uPAR CAR T cells reverse and prevent aging-associated defects in intestinal regeneration and fitness.Nature aging · 2026Article
- Immune-based cancer therapies: mechanistic insights, clinical progress, and future directions.Journal of the Egyptian National Cancer Institute · 2025Review
- Immuno-positron emission tomography as a new frontier in imaging hematologic malignancies.World journal of clinical oncology · 2025Review
- Revolutionizing cardiac fibrosis treatment: the potential of personalized CAR T-cell therapy.Cardio-oncology (London, England) · 2025Review
- Aging and immunity: the age-old tango.Genes & development · 2025Review
- Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Cellular therapies in rheumatic and musculoskeletal diseases.Journal of translational autoimmunity · 2025Review
- Depletion of alloreactive B cells by drug-resistant chimeric alloantigen receptor T cells to prevent transplant rejection.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- [Preparation of Trop2-Targeted CAR-T Cells Based on Nanobodies and Their Antitumor Effects Against Non-Small Cell Lung Cancer].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025Article
- IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors.Journal for immunotherapy of cancer · 2024Article
- In vivo human T cell engineering with enveloped delivery vehicles.Nature biotechnology · 2024Article
- Calibrated CAR Signaling Enables Low-Dose Therapy in Large B-Cell Lymphoma.Research square · 2024Article
- CAR-Aptamers Enable Traceless Enrichment and Monitoring of CAR-Positive Cells and Overcome Tumor Immune Escape.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies.Blood advances · 2024Review
- Disruption of SUV39H1-Mediated H3K9 Methylation Sustains CAR T-cell Function.Cancer discovery · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Spearheaded by the therapeutic use of chimeric antigen receptors (CARs) targeting CD19, synthetic immunology has entered the clinical arena. CARs are recombinant receptors for antigen that engage cell surface molecules through the variable region of an antibody and signal through arrayed T-cell activating and costimulatory domains. CARs allow redirection of T-cell cytotoxicity against any antigen of choice, independent of MHC expression. Patient T cells engineered to express CARs specific for CD19 have yielded remarkable outcomes in subjects with relapsed/refractory B- cell malignancies, setting off unprecedented interest in T-cell engineering and cell-based cancer immunotherapy. In this review, we present the challenges to extend the use of CAR T cells to solid tumors and other pathologies. We further highlight progress in CAR design, cell manufacturing, and genome editing, which in aggregate hold the promise of generating safer and more effective genetically instructed immunity. Novel engineered cell types, including innate T-cell types, natural killer (NK) cells, macrophages, and induced pluripotent stem cell-derived immune cells, are on the horizon, as are applications of CAR T cells to treat autoimmunity, severe infections, and senescence-associated pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.